Tail-vein injection of mannan-binding lectin DNA leads to high expression levels of multimeric protein in liver

被引:25
作者
Vorup-Jensen, T
Jensen, UB
Liu, H
Kawasaki, T
Uemura, K
Thiel, S
Dagnæs-Hansen, F
Jensen, TG
机构
[1] Aarhus Univ, Dept Human Genet, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark
[3] Kyoto Univ, Dept Biol Chem, Grad Sch Pharmaceut Sci, Japan Sci & Technol Corp,Sakyo Ku, Kyoto 6068501, Japan
[4] Kyoto Univ, Core Res Evolut Sci & Technol Project, Grad Sch Pharmaceut Sci, Japan Sci & Technol Corp,Sakyo Ku, Kyoto 6068501, Japan
关键词
nonviral gene therapy; mannan-binding lectin deficiency; innate immunity; complement;
D O I
10.1006/mthe.2001.0335
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The human plasma protein mannan-binding lectin (MBL) is an essential part of the innate immune defense system. Low levels of MBL are associated with recurrent infections and other clinically significant signs of a compromised immune defense. Previous studies have addressed the possibility of reconstitution therapy by the use of recombinant or plasma-derived protein. Natural MBL is a multimeric protein, which consists of up to 18 identical polypeptide chains. Synthesis by in vitro methods of MBL with the proper multimeric structure is difficult. We here report that mice obtain MBL levels comparable to those found in normal human plasma when injected with an MBL expression construct as naked plasmid DNA contained in a large volume of physiologic salt solution. The expression was confined to the liver and high MBL expression levels were obtained with less than 5% of the liver cells transfected. The multimeric structure of the MBL found in plasma of injected mice was similar to that of natural MEL. Thus, liver expression following injection of naked DNA is an alternative to reconstitution therapy with a protein having a complex quaternary structure.
引用
收藏
页码:867 / 874
页数:8
相关论文
共 47 条
[1]  
Anderson WF, 1998, NATURE, V392, P25
[2]  
Budker V, 1996, GENE THER, V3, P593
[3]  
Budker V, 2000, J GENE MED, V2, P76, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<76::AID-JGM97>3.0.CO
[4]  
2-4
[5]   Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J].
Cavazzana-Calvo, M ;
Hacein-Bey, S ;
Basile, CD ;
Gross, F ;
Yvon, E ;
Nusbaum, P ;
Selz, F ;
Hue, C ;
Certain, S ;
Casanova, JL ;
Bousso, P ;
Le Deist, F ;
Fischer, A .
SCIENCE, 2000, 288 (5466) :669-672
[6]  
Christiansen OB, 1999, SCAND J IMMUNOL, V49, P193
[7]   MANNOSE-BINDING PROTEIN GENE POLYMORPHISM IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
DAVIES, EJ ;
SNOWDEN, N ;
HILLARBY, MC ;
CARTHY, D ;
GRENNAN, DM ;
THOMSON, W ;
OLLIER, WER .
ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :110-114
[8]   Characterization of truncated human mannan-binding protein (MBP) expressed in Escherichia coli [J].
Eda, S ;
Suzuki, Y ;
Kawai, T ;
Ohtani, K ;
Kase, T ;
Sakamoto, T ;
Wakamiya, N .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 1998, 62 (07) :1326-1331
[9]   A HUMAN MANNOSE-BINDING PROTEIN IS AN ACUTE-PHASE REACTANT THAT SHARES SEQUENCE HOMOLOGY WITH OTHER VERTEBRATE LECTINS [J].
EZEKOWITZ, RAB ;
DAY, LE ;
HERMAN, GA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (03) :1034-1046
[10]   The mannan-binding-lectin pathway of the innate immune response [J].
Gadjeva, M ;
Thiel, S ;
Jensenius, JC .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (01) :74-78